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C“I’ll be more enthusiastic about encouraging thinking outside the
box when there’s evidence of any thinking going on inside it.”
—Terry Pratchett, British author and commentator (1)
The current guidelines for cardiac resynchronization
herapy include patients with New York Heart Association
unctional class III to IV heart failure, an ejection fraction of
35%, QRS duration 120 ms, on optimal medical ther-
py, and in sinus rhythm (2,3). To this, the European
uidelines add that patients should show evidence of left
entricular dilation. Both American College of Cardiology/
merican Heart Association and European guidelines in-
lude atrial fibrillation as a Class IIa indication, as well as
ermanent pacing, although the American College of Car-
iology/American Heart Association guidelines limit the
ndication to patients who are frequently dependent on
entricular pacing.
Interestingly, despite the homogeneity of these guide-
ines, there are significant variations in the performance
f cardiac resynchronization therapy (CRT) in patients
ith heart failure in both the U.S. (4) and Europe (5).
his heterogeneity is influenced by age, comorbidity,
ocal reimbursement, the number of conventional im-
lantable cardioverter-defibrillator implantations and
raining, and surprisingly less influenced by gross domes-
ic product or health care spending. Indeed, clinical
ractice has drifted away from the evidence base from
linical trials, involving patients who are older and with
ore comorbidities, with 10% having ejection fraction of
35% and 6% having an ejection fraction of 40% (4)
nd often even borderline QRS durations. The appropri-
te implantation rate remains difficult to define, despite
pproximately 40% of patients with systolic heart failure
aving a QRS duration 120 ms (6); only 12% of heart
ailure patients reported by Piccini et al. (4) underwent
RT. There is no doubt that defining the appropriate
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ccepted May 17, 2010.opulation for CRT remains an important challenge, as
he technique is expensive (particularly when replacement
evices are taken into account) and not without risk. A
undamental question is not only whether we should be
atisfied with the populations recommended in the guide-
ines, but whether we should be satisfied with the
pplication of the guidelines themselves.
The review of CRT indications in the current issue of
he Journal suggests that guideline application is too
estrictive (7). These authors focus particularly on addi-
ional groups of patients who are not captured by the
urrent guidelines, including those with a narrow QRS
nd individuals with early heart failure. Nonetheless,
lthough it is true that 40% to 50% of such patients may
ave evidence of mechanical dyssynchrony (by 1 of a
ultitude of published criteria), the published studies of
he efficacy of intervention are far from encouraging.
espite favorable single-center studies, multicenter stud-
es of CRT in patients with a narrower QRS failed to
rovide a uniform message (8,9). Likewise, of the 2
tudies of CRT in early heart failure, the primary end
oint in the REVERSE (Resynchronization Reverses
emodeling in Systolic Left Ventricular Dysfunction)
rial was not attained at 12 months, even though it was
ttained in a subgroup followed to 24 months and various
econdary end points improved (10). In the second study
11), the primary end point of heart failure and death was
ttained due to a reduction of heart failure presentations
ith CRT. Generally, secondary end points should not
e analyzed if the primary end point does not demon-
trate clear statistical significance (12). Broadening of the
ndications for CRT to new populations will be depen-
ent on a number of new studies, which are currently in
rogress (Table 1).
An alternative critique of the current CRT guidelines
ould perhaps be to question whether they are too broad.
he current guidelines take no cognizance of a number of
eatures that may compromise the ability of an individual
atient to mount either a physiologic or survival response to
RT. CRT may face challenges in improving an already-ynchronous ventricle—whether this is defined by mechan-
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Extending the Use of CRT August 31, 2010:763–5cal or electrical synchrony (13,14). Nonsynchrony issues
nclude the impact of underlying etiology, the extremes of
entricular impairment, and comorbidities. A recurrent
heme in CRT is the extent to which the presence of
schemic heart disease may limit the therapeutic response.
lthough it may not impact the survival benefit of CRT,
ailure to improve the physiologic response is often a
roblem for the patient’s expectations of the treatment. It
ow appears that there are a number of situations where the
entricle is unable to respond to CRT. Scarring, particularly
nvolving the posterior wall, limits response (15,16), and
xtensive myocardial scar or lack of contractile reserve may
lso pose a problem (17). Ventricles that are at the extremes
f left ventricular enlargement have been shown in previous
tudies to be unlikely to respond to myocardial revascular-
zation and similarly may be unlikely to respond to CRT.
he presence of extremes of dyssynchrony may have a
imilar effect (18,19). Likewise, shorter QRS duration
150 ms) and non-left bundle-branch block morphology
ave accumulating support for being associated with the
owest success rates. The presence of severe right ventricular
ysfunction and pulmonary hypertension may have a similar
ffect, as may chronic pulmonary disease, valvular disease,
eripheral vascular disease, and end-stage renal disease.
Understandably, the current guidelines reflect the evi-
ence base for CRT. Nonetheless, the algorithm for this
eeds to be broadened to consider not only the degree of
echanical dyssynchrony, but also features of the left
entricle that will prevent response. Developing the evi-
ence base within the population that we currently implant
ay be just as important as extending the population to
ther patients.
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